PHASE-I-II STUDY OF ISOTOPIC IMMUNOGLOBULIN THERAPY FOR PRIMARY LIVER-CANCER

Abstract

A phase I-II study of isotopic Ig therapy was performed in 18 patients with primary liver cancer; 14 were evaluated for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in 6 of 9 patients who were evaluated for response. Further clinical studies with isotopic Ig are indicated.